Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Ziopharm Oncology IN (ZIOP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 660,537
  • Shares Outstanding, K 162,294
  • Annual Sales, $ 150 K
  • Annual Income, $ -53,120 K
  • 60-Month Beta 2.63
  • Price/Sales 4,613.15
  • Price/Cash Flow N/A
  • Price/Book 6.91

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.09
  • Number of Estimates 4
  • High Estimate -0.07
  • Low Estimate -0.10
  • Prior Year -0.15
  • Growth Rate Est. (year over year) +40.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.66 +11.20%
on 03/27/19
4.61 -11.71%
on 04/05/19
+0.22 (+5.71%)
since 03/18/19
3-Month
1.92 +111.98%
on 01/23/19
4.61 -11.71%
on 04/05/19
+1.80 (+79.30%)
since 01/18/19
52-Week
1.56 +160.90%
on 12/27/18
5.00 -18.60%
on 05/31/18
-0.40 (-8.95%)
since 04/18/18

Most Recent Stories

More News
Consolidated Research: 2019 Summary Expectations for ZIOPHARM Oncology, Airgain, Liquidity Services, Kindred Biosciences, Landmark Infrastructure Partners LP, and Sensus Healthcare -- Fundamental Analysis, Key Performance Indications

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of ZIOPHARM Oncology Inc (NASDAQ:ZIOP),...

KIN : 8.74 (+0.69%)
AIRG : 15.45 (-6.25%)
LQDT : 6.48 (+0.62%)
SRTS : 6.16 (-1.44%)
LMRK : 16.20 (+0.19%)
ZIOP : 4.07 (-1.93%)
Ziopharm Oncology Announces FDA Fast Track Designation for Ad-RTS-hIL-12 plus Veledimex for the Treatment of Recurrent Glioblastoma

Ziopharm Oncology, Inc. (Nasdaq: ZIOP), a clinical stage immuno-oncology company developing next generation cell and gene therapies, today announced that the U.S. Food and Drug Administration (FDA) has...

ZIOP : 4.07 (-1.93%)
Ziopharm Oncology Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

- Phase 1 Trial of Sleeping Beauty-TCR-T cell therapy for patients with solid tumors to begin at National Cancer Institute in mid-2019 -

ZIOP : 4.07 (-1.93%)
Intrexon (XON) Reports Narrower-Than-Expected Loss in Q4

Intrexon (XON) incurs narrower-than-expected loss in the fourth quarter of 2018.

CELG : 93.76 (-0.57%)
BGNE : 119.80 (-1.02%)
XON : 4.11 (-7.43%)
ZIOP : 4.07 (-1.93%)
Ziopharm Oncology CEO to Present at the CAR-TCR Summit Europe

Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced that Chief Executive Officer Laurence Cooper, M.D., Ph.D, is scheduled to present and participate in a panel discussion on Feb. 26 at the CAR-TCR Summit...

ZIOP : 4.07 (-1.93%)
Recent Analysis Shows Lattice Semiconductor, ZIOPHARM Oncology, Ferro, SYNNEX, AxoGen, and Twin Disc Market Influences -- Renewed Outlook, Key Drivers of Growth

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Lattice Semiconductor Corporation...

AXGN : 20.84 (-0.76%)
LSCC : 12.66 (+0.40%)
ZIOP : 4.07 (-1.93%)
SNX : 107.27 (-0.17%)
FOE : 18.32 (-1.29%)
TWIN : 16.65 (+1.52%)
Ziopharm Oncology Completes Enrollment of Controlled IL-12 Monotherapy Expansion Substudy in Phase 1 Brain Cancer Trial

Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced that it rapidly completed enrollment and treated a total of 36 patients in less than six months in a substudy (Clinicaltrials.gov NCT03679754) to expand...

ZIOP : 4.07 (-1.93%)
Look for Shares of Ziopharm Oncolog to Potentially Rebound after Yesterday's 5.73% Sell Off

Ziopharm Oncolog (NASDAQ:ZIOP) traded in a range yesterday that spanned from a low of $2.13 to a high of $2.35. Yesterday, the shares fell 5.7%, which took the trading range below the 3-day low of $2.18...

ZIOP : 4.07 (-1.93%)
Biotech Stocks on the Move

HENDERSON, NV / ACCESSWIRE / January 21, 2019 / Biotech has been one of the hottest sectors this month. Investors are intrigued by the increase in M&A. Now's a great time to start researching some oversold...

TCON : 0.71 (-2.74%)
TYME : 1.52 (-6.17%)
ZIOP : 4.07 (-1.93%)
DCTH : 0.1450 (-13.59%)
MNKD : 1.53 (-0.65%)
Ziopharm Oncology Posts Letter to Stockholders

Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today posted and released the following letter:

ZIOP : 4.07 (-1.93%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade ZIOP with:

Business Summary

ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and...

See More

Key Turning Points

2nd Resistance Point 4.41
1st Resistance Point 4.24
Last Price 4.07
1st Support Level 3.94
2nd Support Level 3.81

See More

52-Week High 5.00
Last Price 4.07
Fibonacci 61.8% 3.69
Fibonacci 50% 3.28
Fibonacci 38.2% 2.87
52-Week Low 1.56

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar